Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Arthur E. Frankel, Renuka Reddy, Kayla R. DeSuza, Khaled Deeb, Aaron F. Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T. Silver, Hans C. Hasselbalch

Research output: Contribution to journalArticlepeer-review

Abstract

An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.

Original languageEnglish (US)
Pages (from-to)2228-2235
Number of pages8
JournalClinical Case Reports
Volume9
Issue number4
DOIs
StatePublished - Apr 2021
Externally publishedYes

Keywords

  • COVID-19
  • interferon
  • ruxolitinib

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib'. Together they form a unique fingerprint.

Cite this